Sabizabulin, a Potent Orally Bioavailable Colchicine Binding Site Agent, Suppresses HER2+ Breast Cancer and Metastasis

Sabizabulin, a Potent Orally Bioavailable Colchicine Binding Site Agent, Suppresses HER2+ Breast Cancer and Metastasis

HER2+ breast cancer accounts for 15% of all breast cancer cases. Current frontline therapy for HER2+ metastatic breast cancer relies on targeted antibodies, trastuzumab and pertuzumab, combined with microtubule inhibitors in the taxane class (paclitaxel or docetaxel). It is well known that the clini...

Full description

Bibliographic Details
Main Authors: Raisa I. Krutilina, Kelli L. Hartman, Damilola Oluwalana, Hilaire C. Playa, Deanna N. Parke, Hao Chen, Duane D. Miller, Wei Li, Tiffany N. Seagroves
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
HER2<sup>+</sup> breast cancer
colchicine binding site inhibitor
orally available tubulin inhibitor
patient-derived xenograft
tumor metastasis
Online Access:https://www.mdpi.com/2072-6694/14/21/5336

Internet

https://www.mdpi.com/2072-6694/14/21/5336

Similar Items